Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | MDM4 | O15151 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528567 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL260631 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL178698 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29359997 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL178733 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29423590 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401604 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119708 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL18148920 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119709 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3603648-B1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | SHIONOGI & CO (JP) | 2025-09-17 | — | — | EP | disclosed |
| US-20250108124-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4340859-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | Biohaven Therapeutics Ltd. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117412761-A | Antibody drug conjugates for delivery of cytotoxic agents using MATE technology | 拜奥海芬治疗学有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
| WO-2023090935-A1 | METHOD FOR PRODUCING AGM PEPTIDES THAT BIND SPECIFICALLY TO NUCLEOLIN | 애니젠 주식회사 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
| WO-2023069502-A2 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | RESOLUTE BIO, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230102309-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | Ascendis Pharma Oncology Division A/S (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| WO-2022246086-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986478-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | KMT2A 1076/4885MDM2 3352/4885MDM4 2238/4885 |
| US-20250108124-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | CD47, DOCK2, DOCK5 | KMT2A 465/4885MDM2 1398/4885MDM4 560/4885 |
| US-20230102309-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | ABL1, ERBB2, ROS1 | KMT2A 157/4885MDM2 403/4885MDM4 2584/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | KMT2A 2443/4885MDM2 424/4885MDM4 811/4885 |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | KMT2A 3576/4885MDM2 2022/4885MDM4 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.